TABLE 4.
PRIMARY AND SECONDARY OUTCOMES BY GENOTYPE AT THE END OF THE SALMETEROL TREATMENT PERIOD (VISIT 3) AND AS CHANGE FROM VISIT 2
| Outcomes | End of Treatment Arg16Arg (n = 12) | End of Treatment Gly16Gly (n = 14) | P Value* | Change (V2 to V3) Arg16Arg (n = 12) | Change (V2 to V3) Gly16Gly (n = 14) | P Value† |
|---|---|---|---|---|---|---|
| FEV1 preexercise, % predicted | 84.7 ± 3.6 | 89.0 ± 3.1 | 0.37 | 4.2 ± 2.7 | 4.6 ± 2.6 | 0.91 |
| Morning PEF, L/min | 403.8 ± 17.5 | 483.1 ± 30.8 | 0.04 | 33.3 ± 7.0 | 43.5 ± 13.2 | 0.51 |
| ACQ | 0.8 ± 0.2 | 0.8 ± 0.2 | 0.88 | −0.5 ± 0.2 | −0.2 ± 0.2 | 0.10 |
| FeNO, ppb | 46.6 ± 29.3 | 44.0 ± 7.6 | 0.77 | −1.0 ± 5.5 | −10.9 ± 6.5 | 0.26 |
| FEV1 9 h after salmeterol, % predicted | 88.1 ± 2.8 | 91.9 ± 3.1 | 0.38 | −3.3 ± 1.3 | −0.1 ± 1.3 | 0.10 |
| FEV1 9 h after salmeterol, % increase from preexercise | 3.4 ± 1.9 | 3.5 ± 1.8 | 0.94 | −7.4 ± 2.7 | −4.6 ± 2.2 | 0.43 |
| Max FEV1 % fall | 20.2 ± 5.6 | 25.1 ± 3.4 | 0.45 | 12.6 ± 4.5 | 16.5 ± 2.9 | 0.48 |
| % Bronchoprotection | 21.5 ± 23.4 | 16.6 ± 9.6 | 0.84 | −48.1 ± 20.3 | −54.3 ± 9.3 | 0.77 |
Definition of abbreviations: ACQ = asthma control questionnaire; FeNO = exhaled nitric oxide.
Data are expressed as mean ± SE.
*
Comparison between genotypes in absolute values at the end of treatment.
†
Comparison between genotypes as change from the beginning to the end of treatment.